Novavax’s COVID-19 vaccine shows promising results in first trial
Category: #health  By Nikita Chaurasia  Date: 2020-08-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Novavax’s COVID-19 vaccine shows promising results in first trial

America-based vaccine development company Novavax Inc. has reportedly announced a potential COVID-19 vaccine which showcased a promising immune response in the early stage of its clinical trial. The trials for phase one were conducted at two sites in Australia and comprised of over 131 healthy participants between the age group of 18-59, reported sources.

According to the company, around 106 participants received one of four dose levels of the potential COVID-19 vaccine called NVX-CoV2373, while the other 25 patients received a placebo. These participants were administered two doses of the vaccine through an intramuscular injection with 21 days apart.

Novavax mentioned in a comment that the potential vaccine developed neutralizing antibodies, which according to researchers, are essential in building immunity against the virus as well as killer T-cells. These neutralizing antibodies recorded to be higher than patients recovered from coronavirus. The company also stated that the immune response was stronger among patients who had adjuvant.

If sources are to be believed, Novavax’s COVID-19 vaccine was well tolerated by almost all patients and no severe events were observed. In fact, most patients witnessed pain and tenderness at the injection following the first dose, while some were reported to have muscle aches, fatigue, and headaches. Only one patient apparently experienced a mild fever after the second dose.

Novavax’s President of Research & Development Gregory Glenn was reported saying that the data from the phase-1 trials demonstrated that NVX-CoV2373 along with Matrix-M adjuvant is a well-tolerated coronavirus vaccine with a better immunogenicity profile.

Although the company’s data appears to be promising, Novavax stocks fell briefly over the concerns regarding the safety of the potential vaccine. The shares of the biotech firm dropped by 32% during after-hours trading which later recovered and rose by 7%.

In other news, last month the U.S. government had allotted USD 1.6 billion to Novavax to cover testing, manufacturing, and commercialization costs for a potential coronavirus vaccine. The company reportedly aims to provide 100 million doses by the year 2021.

Source Credits –

https://www.cnbc.com/2020/07/07/us-government-awards-novavax-1point6-billion-for-coronavirus-vaccine.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
By Nikita Chaurasia

According to reliable sources, Massachusetts-headquartered clinical stage biopharmaceutical company, Syndax Pharmaceuticals Inc. has revealed an updated data from its Phase 1 trial of its patent axatilimab. The company will reportedly present the dat...

Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
By Nikita Chaurasia

Shares of Xiaomi Corporation, a Chinese multinational electronics company, witnessed a 7.1% drop during Hong Kong trading after the company secured USD 3.91 billion in fund raising which also included the city’s top-up placement. The company h...

Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
By Nikita Chaurasia

Israel-based leading provider of advanced solutions for cybersecurity, IoT (Internet of Things) and e-Government sectors Supercom has reportedly signed a supply agreement to deliver its PureSecurity EM (Electronic Monitoring) product suite in Wiscons...